Furthermore, the PARP pathway represents a promising target for treatment of autoimmune conditions, including type 1 diabetes, glomerulonephritis, multiple sclerosis, and rheumatoid arthritis [1, 25, 33]. Here, PARP1 is linked to type 1 diabetes mellitus.